Can short-term hormone therapy for rising PSA prolong survival?
- 1 June 2016
- journal article
- editorial
- Published by Elsevier in The Lancet Oncology
- Vol. 17 (6) , 687-688
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trialThe Lancet Oncology, 2016
- Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSAInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2016
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2015
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyNew England Journal of Medicine, 2014
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyNew England Journal of Medicine, 2013
- Salvage Radiotherapy for Recurrent Prostate Cancer After Radical ProstatectomyJAMA, 2004